79 filings
Page 2 of 4
8-K
qemxmfpx4i7zxvjwnsn7
27 Sep 22
Other Events
5:00pm
8-K
mq26zyeor 4nnum0
12 Aug 22
PhaseBio Pharmaceuticals Reports Second Quarter 2022 Financial Results and Recent Business Highlights
8:32am
8-K
cj094m04ur4qgucqqkb
8 Aug 22
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
4:14pm
8-K
641iogamcq 5uy00lv
5 Jul 22
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
4:31pm
8-K
9w9rc2 r3sa5l
20 May 22
Submission of Matters to a Vote of Security Holders
4:29pm
8-K
q7mk7
16 May 22
PhaseBio Pharmaceuticals Reports First Quarter 2022 Financial Results and Recent Business Highlights
12:00am
8-K
ak5n9
4 Apr 22
PhaseBio Announces Positive Results from Phase 2b Trial for Bentracimab
4:35pm
8-K
2usdkihp5 sxjyiptab1
24 Mar 22
PhaseBio Pharmaceuticals Reports Fourth Quarter and Full-Year 2021 Financial Results and Provides Recent Business Highlights
4:12pm
8-K
0p7cb26zhs44aanl5fv
21 Dec 21
PhaseBio Provides Pemziviptadil (PB1046) Program Update
8:03am
8-K
oeqeu55c 8u
15 Nov 21
Regulation FD Disclosure
11:32am
8-K
oza5 u8fy6ids19
10 Nov 21
PhaseBio Reports Third-Quarter 2021 Financial Results and Recent Business Highlights
4:35pm
8-K
re2lamsn3ixw27f1
3 Nov 21
PhaseBio Announces Topline Results from Phase 2b Trial for Bentracimab
8:04am
8-K
ix5q0tc
15 Sep 21
PhaseBio Appoints William D. Humphries to Board of Directors
8:04am
8-K
ij0998 dmq
12 Aug 21
PhaseBio Reports Second-Quarter 2021 Financial Results and Recent Business Highlights
10:11am
8-K
d4bbw8nc ej2
10 Aug 21
PhaseBio Pharmaceuticals and SFJ Pharmaceuticals® Announce Approval of IND Application in China for Bentracimab
8:03am
8-K
0fcg12vr8yhmz thy6r
17 Jun 21
PhaseBio Announces European Licensing Agreement with Alfasigma S.p.A for Commercialization of Bentracimab
8:13am
8-K
iwmlusu8q 43zf0d
4 Jun 21
Submission of Matters to a Vote of Security Holders
5:00pm
8-K
0u2lakvk
13 May 21
PhaseBio Reports First-Quarter 2021 Financial Results and Recent Business Highlights
4:06pm
8-K
64190
19 Mar 21
PhaseBio Announces Pricing of Public Offering of Common Stock
4:08pm
8-K
4mmdr6
15 Mar 21
PhaseBio Reports Fourth-Quarter and Full-Year 2020 Financial Results and Recent Business Highlights
8:10am